Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Disc Medicine Inc IRON

Healthcare Biotechnology
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond... see more

Recent & Breaking News (NDAQ:IRON)

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

GlobeNewswire 3 days ago

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

GlobeNewswire 4 days ago

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8 days ago

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

GlobeNewswire April 1, 2024

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 21, 2024

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

GlobeNewswire March 6, 2024

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

GlobeNewswire February 26, 2024

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

GlobeNewswire February 20, 2024

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

GlobeNewswire February 9, 2024

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

GlobeNewswire February 7, 2024

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

GlobeNewswire December 20, 2023

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 11, 2023

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 11, 2023

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

GlobeNewswire November 14, 2023

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 9, 2023

Disc Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire November 8, 2023

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

GlobeNewswire November 2, 2023

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

GlobeNewswire October 23, 2023

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

GlobeNewswire October 3, 2023